Skip to main content

Advertisement

SpringerLink
Log in

Statins use and recurrent venous thromboembolism in the direct oral anticoagulant era: insight from the COMMAND VTE Registry-2

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Statins were reported to have a potential effect of primary prevention of venous thromboembolism (VTE), although that of secondary prevention remains uncertain. To investigate the association between statins use and recurrent VTE in the current era. The COMMAND VTE Registry-2 is a multicenter registry enrolling 5,197 consecutive VTE patients among 31 centers in Japan between January 2015 and August 2020. We divided the entire cohort into 2 groups according to statins use at the time of discharge; the statins (N = 865) and no statins groups (N = 4332). The statins group was older (72.9 vs. 66.7 years, P < 0.001), and less often had active cancer (22.0% vs. 30.4%, P < 0.001). The cumulative incidence of discontinuation of anticoagulation was significantly lower in the statins group (60.3% vs. 52.6%, Log-rank P < 0.001). The cumulative 5-year incidence of recurrent VTE was significantly lower in the statins group (6.8% vs. 10.1%, Log-rank P = 0.01). Even after adjusting for the confounders, the lower risk of the statins group relative to the no statins group remained significant for recurrent VTE (HR 0.65, 95% CI 0.45–0.91, P = 0.01). The cumulative 5-year incidence of major bleeding was significantly lower in the statins group (12.2% vs. 14.1%, Log-rank P = 0.04), although, after adjusting for the confounders, the risk of the statins group relative to the no statins group turned to be insignificant (HR 0.77, 95% CI 0.59–1.00, P = 0.054). In this large real-world VTE registry, statins use was significantly associated with a lower risk for the recurrent VTE in the current era.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. However, if the relevant review board or ethics committee approve data sharing and all investigators of the COMMAND VTE Registry-2 provide consent, the deidentified participant data will be shared on a request basis through the principal investigator. Study protocol will also be available. The data will be shared as Excel files via e-mail during the proposed investigation period.

Abbreviations

CI:

Confidence interval

DOAC:

Direct oral anticoagulant

IOM:

Deep vein thrombosis

HR:

Hazard ratio

LDL:

Low-density lipoprotein

PE:

Pulmonary embolism

VTE:

Hazard ratio

References

  1. Oleksiuk-Bójko M, Lisowska A (2023) Venous thromboembolism: why is it still a significant health problem? Adv Med Sci 68(1):10–20. https://doi.org/10.1016/j.advms.2022.10.002

    Article  PubMed  Google Scholar 

  2. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ et al (2021) Antithrombotic therapy for VTE Disease: second update of the CHEST Guideline and Expert Panel Report. Chest 160(6):e545–e608. https://doi.org/10.1016/j.chest.2021.07.055

    Article  CAS  PubMed  Google Scholar 

  3. Oesterle A, Laufs U, Liao JK (2017) Pleiotropic effects of statins on the Cardiovascular System. Circ Res 120:229–243. https://doi.org/10.1161/circresaha.116.308537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Undas A, Celińska-Löwenhoff M, Kaczor M, Musial J (2004) New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 91:1065–1077. https://doi.org/10.1160/th04-02-0064

    Article  CAS  PubMed  Google Scholar 

  5. Undas A, Brummel-Ziedins KE, Mann KG (2005) Statins and blood coagulation. Arterioscler Thromb Vasc Biol. https://doi.org/10.1161/01.atv.0000151647.14923.ec. 25:287 – 94

    Article  PubMed  PubMed Central  Google Scholar 

  6. Biedermann JS, Kruip M, van der Meer FJ, Rosendaal FR, Leebeek FWG, Cannegieter SC et al (2018) Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. Eur Heart J 39:1740–1747. https://doi.org/10.1093/eurheartj/ehy014

    Article  CAS  PubMed  Google Scholar 

  7. Violi F, Calvieri C, Ferro D, Pignatelli P (2013) Statins as antithrombotic drugs. Circulation 127:251–257. https://doi.org/10.1161/circulationaha.112.145334

    Article  PubMed  Google Scholar 

  8. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ et al (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360:1851–1861. https://doi.org/10.1056/nejmoa0900241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kunutsor SK, Seidu S, Khunti K (2017) Statins and primary prevention of venous thromboembolism a systematic review and meta-analysis. Lancet Haematol 4:e83–e93. https://doi.org/10.1016/s2352-3026(16)30184-3

    Article  PubMed  Google Scholar 

  10. Biere-Rafi S, Hutten BA, Squizzato A, Ageno W, Souverein PC, de Boer A et al (2013) Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J 34:1800–1806. https://doi.org/10.1093/eurheartj/eht046

    Article  CAS  PubMed  Google Scholar 

  11. Tagalakis V, Eberg M, Kahn S, Azoulay L (2016) Use of statins and reduced risk of recurrence of VTE in an older population. A population-based cohort study. Thromb Haemost 115:1220–1228. https://doi.org/10.1160/th15-10-0775

    Article  PubMed  Google Scholar 

  12. Yoshikawa Y, Yamashita Y, Morimoto T, Mabuchi H, Amano H, Takase T et al (2020) Effect of statins on recurrent venous thromboembolism (from the COMMAND VTE Registry). Am J Cardiol 125:189–197. https://doi.org/10.1016/j.amjcard.2019.10.011

    Article  CAS  PubMed  Google Scholar 

  13. Delluc A, Tromeur C, Le Moigne E, Nowak E, Mottier D, Le Gal G et al (2012) Lipid lowering drugs and the risk of recurrent venous thromboembolism. Thromb Res 130:859–863. https://doi.org/10.1016/j.thromres.2012.08.296

    Article  CAS  PubMed  Google Scholar 

  14. Brækkan SK, Caram-Deelder C, Siegerink B, van Hylckama Vlieg A, le Cessie S, Rosendaal FR et al (2017) Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Res Pract Thromb Haemost 1:112–119. https://doi.org/10.1002/rth2.12003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kaneda K, Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Ikeda N et al (2023) Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants. Eur J Intern Med 118:59–72. https://doi.org/10.1016/j.ejim.2023.08.007

    Article  CAS  PubMed  Google Scholar 

  16. Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415. https://doi.org/10.1056/nejmoa1306638

    Article  PubMed  Google Scholar 

  17. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694. https://doi.org/10.1111/j.1538-7836.2005.01204.x

    Article  CAS  PubMed  Google Scholar 

  18. Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K et al (2018) Anticoagulation therapy for venous thromboembolism in the Real World　- from the COMMAND VTE Registry. Circ J: Official J Japanese Circulation Soc 82:1262–1270. https://doi.org/10.1253/circj.cj-17-1128

    Article  Google Scholar 

  19. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41:543–603. https://doi.org/10.1093/eurheartj/ehz405

    Article  PubMed  Google Scholar 

  20. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ et al (2021) Antithrombotic therapy for VTE Disease: second update of the CHEST Guideline and Expert Panel Report. Chest 160:e545–e608. https://doi.org/10.1016/j.chest.2021.07.055

    Article  CAS  PubMed  Google Scholar 

  21. Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K et al (2018) Influence of baseline platelet count on outcomes in patients with venous thromboembolism (from the COMMAND VTE Registry). Am J Cardiol 122:2131–2141. https://doi.org/10.1016/j.amjcard.2018.08.053

    Article  PubMed  Google Scholar 

  22. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123:1788–1830. https://doi.org/10.1161/cir.0b013e318214914f

    Article  PubMed  Google Scholar 

  23. Ando MFI, Ito M, Kobayashi T, Masuda M, Miyahara Y, Nakanishi N et al (2011) Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J: Official J Japanese Circulation Soc 75:1258–1281. https://doi.org/10.1253/circj.cj-88-0010

    Article  Google Scholar 

  24. Joseph P, Glynn R, Lonn E, Ramasundarahettige C, Eikelboom J, MacFadyen J et al (2022) Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. Cardiovasc Res 118:897–903. https://doi.org/10.1093/cvr/cvab078

    Article  CAS  PubMed  Google Scholar 

  25. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117:93–102. https://doi.org/10.1161/circulationaha.107.709204

    Article  PubMed  Google Scholar 

  26. Zaccardi F, Kunutsor SK, Seidu S, Davies MJ, Khunti K (2018) Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis 271:223–231. https://doi.org/10.1016/j.atherosclerosis.2018.02.035

    Article  CAS  PubMed  Google Scholar 

  27. Arshad N, Bjøri E, Hindberg K, Isaksen T, Hansen JB, Braekkan SK (2017) Recurrence and mortality after first venous thromboembolism in a large population-based cohort. J Thromb Haemost 15:295–303. https://doi.org/10.1111/jth.13587

    Article  CAS  PubMed  Google Scholar 

  28. Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41:3–14. https://doi.org/10.1007/s11239-015-1311-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kronenberg RM, Beglinger S, Stalder O, Méan M, Limacher A, Beer JH et al (2019) Statin therapy and recurrent venous thromboembolism in the elderly: a prospective cohort study. Sci Rep 9:14804. https://doi.org/10.1038/s41598-019-51374-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kunutsor SK, Seidu S, Khunti K (2017) Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J 38:1608–1612

    Article  PubMed  PubMed Central  Google Scholar 

  31. Zhu H, Zheng H, Xu T, Liu X, Liu X, Sun L et al (2022) Effects of statins in primary and secondary prevention for venous thromboembolism events: a meta analysis. Vascul Pharmacol 142:106931. https://doi.org/10.1093/eurheartj/ehx107

    Article  CAS  PubMed  Google Scholar 

  32. Li R, Yuan M, Yu S, Fu W, Yu W, Ling S et al (2021) Effect of statins on the risk of recurrent venous thromboembolism: a systematic review and meta-analysis. Pharmacol Res 165:105413. https://doi.org/10.1016/j.phrs.2020.105413

    Article  CAS  PubMed  Google Scholar 

  33. Hemkens LG, Benchimol EI, Langan SM, Briel M, Kasenda B, Januel JM et al (2016) The reporting of studies using routinely collected health data was often insufficient. J Clin Epidemiol 79:104–111. https://doi.org/10.1016/j.jclinepi.2016.06.005

    Article  PubMed  PubMed Central  Google Scholar 

  34. Chaffey P, Thompson M, Pai AD, Tafreshi AR, Tafreshi J, Pai RG (2018) Usefulness of statins for Prevention of venous thromboembolism. Am J Cardiol 121:1436–1440. https://doi.org/10.1016/j.amjcard.2018.02.024

    Article  CAS  PubMed  Google Scholar 

  35. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207. https://doi.org/10.1056/nejmoa0807646

    Article  CAS  PubMed  Google Scholar 

  36. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B et al (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (London England) 385:1397–1405. https://doi.org/10.1016/s0140-6736(14)61368-4

    Article  PubMed  Google Scholar 

  37. Ridker PM, Miletich JP, Hennekens CH, Buring JE (1997) Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 277(16):1305–1307. https://jamanetwork.com/journals/jama/article-abstract/415610

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors appreciate the support and collaboration of the coinvestigators participating in the COMMAND VTE Registry-2.

Funding

The COMMAND VTE Registry-2 is partially supported by JSPS KAKENHI (grant number: JP21K16022). The research funding body had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Author information

Authors and Affiliations

  1. Department of Cardiology, Koto Memorial Hospital, Higashiomi, Japan

    Hiroshi Mabuchi

  2. Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan

    Ryusuke Nishikawa, Yugo Yamashita, Kazuhisa Kaneda & Koh Ono

  3. Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan

    Takeshi Morimoto

  4. Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan

    Ryuki Chatani

  5. Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan

    Yuji Nishimoto

  6. Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan

    Nobutaka Ikeda

  7. Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan

    Yohei Kobayashi

  8. Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Satoshi Ikeda

  9. Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan

    Kitae Kim

  10. Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan

    Moriaki Inoko

  11. Department of Cardiology, Kinki University Hospital, Osaka, Japan

    Toru Takase

  12. Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan

    Shuhei Tsuji

  13. Department of Cardiology, Japanese Red Cross Otsu Hospital, Otsu, Japan

    Maki Oi

  14. Department of Cardiology, Tokyo Women’s Medical University, Tokyo, Japan

    Takuma Takada

  15. Department of General Internal Medicine, Kobe University Hospital, Kobe, Japan

    Kazunori Otsui

  16. Department of Cardiology, Tenri Hospital, Tenri, Japan

    Jiro Sakamoto

  17. Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan

    Yoshito Ogihara

  18. Department of Cardiology, Shiga General Hospital, Moriyama, Japan

    Takeshi Inoue

  19. Department of Cardiology, Kansai Electric Power Hospital, Osaka, Japan

    Shunsuke Usami

  20. Department of Cardiology, Osaka Saiseikai Noe Hospital, Osaka, Japan

    Po-Min Chen

  21. Division of Cardiology, Nara Hospital, Kinki University Faculty of Medicine, Ikoma, Japan

    Kiyonori Togi

  22. Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan

    Norimichi Koitabashi

  23. Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan

    Seiichi Hiramori

  24. Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

    Kosuke Doi

  25. Division of Cardiology, Shimada General Medical Center, Shimada, Japan

    Yoshiaki Tsuyuki

  26. Department of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan

    Koichiro Murata

  27. Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan

    Kensuke Takabayashi & Takeshi Kimura

  28. Department of Cardiovascular Medicine, Sugita Genpaku Memorial Obama Municipal Hospital, Obama, Japan

    Hisato Nakai

  29. Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    Daisuke Sueta

  30. Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan

    Wataru Shioyama & Yoshihisa Nakagawa

  31. Division of Cardiology, Kohka Public Hospital, Koka, Japan

    Tomohiro Dohke

Authors
  1. Hiroshi Mabuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryusuke Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yugo Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeshi Morimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryuki Chatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhisa Kaneda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuji Nishimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobutaka Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yohei Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Satoshi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kitae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Moriaki Inoko
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Toru Takase
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shuhei Tsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Maki Oi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Takuma Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Kazunori Otsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Jiro Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Yoshito Ogihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Takeshi Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Shunsuke Usami
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Po-Min Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Kiyonori Togi
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Norimichi Koitabashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Seiichi Hiramori
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Kosuke Doi
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Yoshiaki Tsuyuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Koichiro Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Kensuke Takabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Hisato Nakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Daisuke Sueta
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. Wataru Shioyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. Tomohiro Dohke
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. Koh Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. Yoshihisa Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. Takeshi Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yugo Yamashita.

Ethics declarations

Research involving human participants and/or animals

The current study was conducted in accordance with the principles of the Declaration of Helsinki. We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

Informed consent

Written informed consent from each patient was waived, because we used clinical information obtained in routine clinical practice. This method is concordant with the guidelines for epidemiological studies issued by the Ministry of Health, Labor, and Welfare in Japan.

Conflicts of interest

Dr. Yamashita received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo and grant support from Bayer Healthcare and Daiichi-Sankyo. Dr. Morimoto reports lecture fees from Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Kyocera, Novartis, and Toray and manuscript fees from Bristol-Myers Squibb and Kowa; he was on the advisory board for Sanofi. Dr. Kaneda received lecture fees from Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo. Dr. Nishimoto received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo. Dr. Ikeda N. received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, and Daiichi-Sankyo. Dr. Ikeda S. received lecture fees from Bayer Healthcare, Bristol-Myers Squibb and Daiichi-Sankyo. Dr. Ogihara received research funding from Bayer Healthcare. Dr. Koitabashi received lecture fees from Bayer Healthcare and grant support from Pfizer. All other authors reported that they have no relationships relevant to the contents of this paper to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mabuchi, H., Nishikawa, R., Yamashita, Y. et al. Statins use and recurrent venous thromboembolism in the direct oral anticoagulant era: insight from the COMMAND VTE Registry-2. J Thromb Thrombolysis (2024). https://doi.org/10.1007/s11239-024-03002-0

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11239-024-03002-0

Keywords

Search

Navigation